Federal Cannabis Taxation: Revenue Projections, Policy Frameworks & Economic Impact

Executive Summary

Federal cannabis taxation represents one of the most significant revenue opportunities and policy challenges facing U.S. lawmakers as the nation moves toward broader marijuana legalization. A recent study estimates that federal taxation of marijuana could generate $57.9 billion in revenue, underscoring the fiscal stakes of cannabis policy reform. Currently, cannabis businesses operate under a punitive tax regime dominated by Internal Revenue Code Section 280E, which prohibits standard business deductions for operations involving Schedule I or II controlled substances. This creates effective tax rates exceeding 70% for many operators, forcing businesses into cash-only operations while the federal government forgoes billions in potential excise tax revenue. As Congress debates rescheduling marijuana from Schedule I to Schedule III and considers comprehensive legalization frameworks, the structure of federal cannabis taxation will determine market viability, state-federal revenue sharing, social equity outcomes, and whether illicit markets can be displaced by regulated commerce. The taxation debate encompasses multiple dimensions: excise tax rates and structures, income tax treatment under 280E, banking access through the SAFE Banking Act, interstate commerce implications, and coordination with 38 state-level programs that have collectively generated over $15 billion in annual tax revenue. Federal policy will ultimately shape whether cannabis taxation follows alcohol and tobacco models or creates an entirely new regulatory framework.

Why Federal Cannabis Taxation Matters

The federal cannabis tax question affects $30 billion in annual U.S. cannabis sales, 428,000 jobs, millions of patients, and the fiscal health of states that have already legalized. For operators, the current 280E regime creates existential business challenges. Multi-state operators like Curaleaf, Trulieve, and Green Thumb Industries report effective tax rates of 70-85%, compared to 21-25% for comparable consumer goods companies. This tax burden prevents profitability, limits capital investment, and makes legal cannabis uncompetitive with illicit markets where prices remain 20-40% lower in states like California and Oregon. For patients, taxation directly impacts medicine affordability. Medical cannabis users spend an average of $200-400 monthly on products that insurance doesn't cover. State excise taxes ranging from 10-37% compound with sales taxes and federal income tax burdens passed through to consumers. In Illinois, total tax rates on adult-use purchases reach 41%, while medical patients face lower but still substantial burdens. For states, federal tax policy determines revenue retention. States collected $3.77 billion in cannabis tax revenue in 2023, funding education, infrastructure, and social equity programs. Federal legalization with excise taxes could either complement state revenues or create competitive pressure that forces states to lower rates, potentially defunding established programs. For the Treasury, the revenue opportunity is substantial. The Congressional Budget Office estimated in 2020 that federal marijuana legalization with a $50-per-ounce excise tax would generate $13.6 billion over ten years. The recent study projecting $57.9 billion suggests even larger fiscal potential depending on tax structure, rate schedules, and market growth assumptions.

Background and History: The Evolution of Federal Cannabis Tax Policy

Federal cannabis taxation has evolved from outright prohibition through punitive tax enforcement to the current debate over optimal revenue structures.

The Marihuana Tax Act of 1937

The federal government's first comprehensive cannabis tax regime began with the Marihuana Tax Act of 1937, which imposed occupational excise taxes on cannabis dealers, physicians, and handlers. Rather than outright prohibition, the Act created a tax structure designed to make legal compliance nearly impossible while generating revenue. The tax was $1 per ounce for authorized medical and industrial uses, but $100 per ounce for unauthorized transfers—equivalent to roughly $2,100 in 2024 dollars. The Supreme Court struck down the Act in Leary v. United States (1969), finding that the registration requirements violated Fifth Amendment protections against self-incrimination. Congress responded by passing the Controlled Substances Act of 1970, which abandoned taxation in favor of criminal prohibition and placed marijuana in Schedule I.

Section 280E: The Modern Tax Weapon (1982-Present)

The current federal tax regime stems from a 1981 Tax Court case, Jeffery Edmondson v. Commissioner. Edmondson, a Minneapolis cocaine, marijuana, and amphetamine dealer, deducted business expenses including packaging, phone bills, and a scale on his tax return. The Tax Court allowed the deductions, finding that even illegal businesses could claim ordinary and necessary expenses under 26 U.S.C. § 162. Congress responded swiftly. In 1982, as part of the Tax Equity and Fiscal Responsibility Act, lawmakers added Section 280E to the Internal Revenue Code: "No deduction or credit shall be allowed for any amount paid or incurred during the taxable year in carrying on any trade or business if such trade or business (or the activities which comprise such trade or business) consists of trafficking in controlled substances (within the meaning of schedule I and II of the Controlled Substances Act) which is prohibited by Federal law or the law of any State in which such trade or business is conducted." The provision targeted drug kingpins. For three decades it remained obscure. Then states began legalizing medical marijuana, creating a new class of taxpayer: state-legal cannabis businesses subject to federal prohibition.

The Collision: State Legalization Meets 280E (1996-2012)

California's Proposition 215 in 1996 created the first modern medical marijuana program, followed by Alaska, Oregon, and Washington in 1998. Early dispensaries operated in legal gray areas, often as nonprofits or cooperatives. The IRS began auditing cannabis businesses in the mid-2000s, applying 280E to disallow all deductions except cost of goods sold (COGS). The landmark case Californians Helping to Alleviate Medical Problems, Inc. v. Commissioner (2007) established the framework. CHAMP, a San Francisco dispensary, attempted to deduct standard business expenses including rent, wages, and utilities. The Tax Court ruled that 280E applied, but allowed COGS deductions for inventory directly sold. This created a critical distinction: cultivators who produce inventory can deduct growing costs as COGS, while retailers who purchase finished goods have minimal COGS and face effective tax rates of 70-90%.

The Expansion Era and 280E Entrenchment (2012-2020)

Colorado and Washington legalized adult-use sales in 2012, followed by Alaska, Oregon, California, Nevada, Massachusetts, Michigan, and others. By 2020, 33 states had medical programs and 11 had adult-use markets. The industry grew to $17.5 billion in annual sales by 2020. The IRS formalized 280E enforcement. In Olive v. Commissioner (2015), the Tax Court disallowed $2.3 million in deductions for a California dispensary, resulting in a $1.2 million tax liability. In Alterman v. Commissioner (2018), the court rejected attempts to separate cannabis sales from non-cannabis activities like caregiving services. Cannabis businesses developed elaborate COGS maximization strategies: allocating overhead to production, reclassifying employees as production workers, and vertical integration to capture cultivation COGS. The Tax Court scrutinized these approaches in Patients Mutual Assistance Collective Corp. v. Commissioner (2015) and other cases, generally limiting aggressive COGS interpretations.

Congressional Reform Efforts (2019-Present)

As the industry matured, reform proposals emerged. The Marijuana Opportunity Reinvestment and Expungement (MORE) Act, first introduced in 2019 and passed by the House in 2020 and 2022, would deschedule cannabis and impose a 5% federal excise tax, escalating to 8% over three years. Revenue would fund social equity programs, expungement, and community reinvestment. The Cannabis Administration and Opportunity Act (CAOA), introduced by Senate Majority Leader Chuck Schumer in 2022, proposed a more complex structure: an initial excise tax based on THC content (starting at 10% of price, escalating to 25%), plus a per-ounce tax after three years. The bill would also eliminate 280E and allow standard deductions. Neither bill has advanced to enactment. The SAFE Banking Act, which would protect financial institutions serving cannabis businesses, has passed the House seven times but stalled in the Senate.

The Rescheduling Debate (2022-Present)

In October 2022, President Biden directed the Department of Health and Human Services and the Department of Justice to review marijuana's Schedule I classification. In August 2023, HHS recommended rescheduling to Schedule III, citing accepted medical use and lower abuse potential than Schedule I or II substances. The DEA published a Notice of Proposed Rulemaking in May 2024, proposing to move marijuana to Schedule III alongside anabolic steroids and ketamine. Schedule III status would eliminate 280E, allowing standard business deductions, but would not legalize cannabis federally or resolve banking issues. The proposal triggered a 60-day comment period and administrative law judge hearings scheduled for late 2024. Rescheduling to Schedule III would reduce effective tax rates from 70-85% to 25-35%, providing significant relief. However, it would maintain federal prohibition, continue banking restrictions, and leave interstate commerce illegal. Industry advocates increasingly view rescheduling as inadequate compared to full descheduling.

Key Players in Federal Cannabis Tax Policy

Internal Revenue Service

The IRS enforces 280E through audits, guidance, and litigation. The agency's Small Business/Self-Employed Division handles cannabis examinations. IRS Chief Counsel has issued multiple memoranda interpreting 280E, including guidance on COGS calculations and the treatment of vertically integrated businesses. The agency collected an estimated $1.8 billion from cannabis businesses in 2022 through 280E enforcement, though precise figures remain unpublished.

Drug Enforcement Administration

The DEA controls scheduling decisions under the Controlled Substances Act. Administrator Anne Milgram oversees the rescheduling process, including the current Schedule III proposal. The agency has historically opposed marijuana legalization, citing international treaty obligations under the 1961 Single Convention on Narcotic Drugs. DEA's administrative law judges will conduct hearings on the rescheduling proposal, with a final rule expected in 2025 or 2026.

Department of Health and Human Services

HHS, through the Food and Drug Administration, conducts scientific evaluations of controlled substances. The FDA's August 2023 recommendation to reschedule marijuana to Schedule III represented a significant policy shift. FDA Commissioner Robert Califf cited evidence of accepted medical use for conditions including chronic pain, nausea from chemotherapy, and appetite stimulation in HIV/AIDS patients.

Congressional Tax Committees

The House Ways and Means Committee and Senate Finance Committee hold jurisdiction over tax legislation. Ways and Means Chairman Jason Smith and Ranking Member Richard Neal have not advanced cannabis tax reform despite House passage of the MORE Act. Senate Finance Committee Chairman Ron Wyden has supported cannabis banking reform but not comprehensive tax restructuring.

Multi-State Operators

Publicly traded MSOs including Curaleaf Holdings, Green Thumb Industries, Trulieve Cannabis, Cresco Labs, and Verano Holdings collectively operate over 900 dispensaries and cultivation facilities. These companies report 280E impacts in quarterly earnings, with Curaleaf disclosing $188 million in disallowed deductions in 2023. MSOs have funded lobbying efforts through the Cannabis Trade Federation and other industry groups, spending an estimated $4.5 million on federal lobbying in 2023.

National Cannabis Industry Association

The NCIA represents over 1,500 cannabis businesses and advocates for 280E repeal, banking access, and rational federal taxation. The organization has published white papers on optimal tax structures, generally supporting excise taxes under 10% to avoid creating price advantages for illicit markets.

Drug Policy Alliance and NORML

These advocacy organizations prioritize social equity and criminal justice reform over industry concerns. The Drug Policy Alliance supports the CAOA's approach of dedicating tax revenue to communities harmed by prohibition. NORML has advocated for descheduling rather than rescheduling, arguing that Schedule III status maintains unnecessary federal control.

Legal and Regulatory Framework

Federal cannabis taxation operates within a complex web of statutes, regulations, and case law that create unique burdens for state-legal businesses. The foundational statute is 26 U.S.C. § 280E, which references the Controlled Substances Act's Schedule I and II classifications at 21 U.S.C. § 812. Because marijuana remains in Schedule I, any business "trafficking" in cannabis cannot deduct ordinary business expenses including rent, salaries (except for production workers included in COGS), marketing, professional fees, utilities, or insurance. The Tax Court has interpreted "trafficking" broadly. In Olive v. Commissioner, the court rejected arguments that state-legal medical dispensaries don't "traffic" in controlled substances, finding that the term encompasses any commercial sale regardless of state law. The court has also rejected attempts to bifurcate cannabis and non-cannabis business lines, ruling in Alterman that ancillary services cannot be separated from cannabis sales for deduction purposes. COGS calculations follow 26 U.S.C. § 471 and Treasury Regulation § 1.471. For cultivators, COGS includes seeds, growing media, nutrients, labor directly involved in cultivation, and allocable overhead. Retailers purchasing finished goods can only deduct the wholesale purchase price. The Tax Court has limited aggressive COGS interpretations, disallowing attempts to allocate general administrative expenses to production in Patients Mutual Assistance Collective. The Internal Revenue Manual provides IRS examiners with guidance on cannabis audits, including document requests, COGS verification, and assessment procedures. IRM 4.10.11 addresses excise taxes on controlled substances, though these provisions predate state legalization and focus on illicit trafficking. Banking restrictions stem from the Bank Secrecy Act (31 U.S.C. § 5311 et seq.) and anti-money laundering regulations. The Financial Crimes Enforcement Network issued guidance in 2014 (FinCEN FIN-2014-G001) allowing banks to serve cannabis businesses if they file Suspicious Activity Reports and conduct enhanced due diligence. However, most banks decline to serve the industry due to federal prohibition and potential criminal liability under 18 U.S.C. § 1956 (money laundering) and 18 U.S.C. § 1957 (monetary transactions in property derived from specified unlawful activity). The SAFE Banking Act would create a safe harbor under 31 U.S.C. § 5318 for financial institutions serving state-legal cannabis businesses. The bill has passed the House seven times but faces Senate opposition from members seeking comprehensive reform rather than incremental banking fixes. Interstate commerce remains prohibited under the Controlled Substances Act's manufacturing and distribution provisions (21 U.S.C. § 841). Even if marijuana moves to Schedule III, interstate transport would require DEA registration and compliance with prescription drug regulations under 21 C.F.R. § 1301. Full interstate commerce would require either descheduling or specific statutory authorization.

State-by-State Tax Structures and Federal Implications

Thirty-eight states have legalized medical or adult-use cannabis with tax rates ranging from zero to 37%, creating a patchwork that federal policy must either harmonize or override.

California

California imposes a 15% excise tax on retail sales, plus state sales tax of 7.25% and local taxes averaging 5-10%. The state eliminated its cultivation tax of $10.08 per ounce in 2022 after it drove operators to illicit markets. California collected $1.29 billion in cannabis tax revenue in fiscal year 2022-23, below projections due to illicit market competition. Federal taxation would compound California's already high burden, potentially requiring state rate reductions.

Colorado

Colorado's structure includes a 15% retail excise tax and 15% wholesale excise tax, plus state sales tax of 2.9%. The state collected $423 million in marijuana tax revenue in fiscal year 2022-23, funding school construction, substance abuse programs, and local governments. Colorado has operated a mature market since 2014, providing a model for federal revenue projections.

Illinois

Illinois employs a tiered excise tax based on THC content: 10% for products under 35% THC, 20% for cannabis-infused products, and 25% for concentrates over 35% THC. Combined with state and local sales taxes, total rates reach 41% in Chicago. The state collected $445 million in fiscal year 2023, with 25% allocated to the Restore, Reinvest, and Renew Program for communities impacted by the war on drugs. Illinois's THC-based structure resembles proposals in the CAOA.

Michigan

Michigan imposes a 10% excise tax on adult-use sales, one of the lowest rates nationally. The state collected $290 million in fiscal year 2022-23. Michigan's lower tax burden has supported rapid market growth, with sales reaching $3 billion annually. The state demonstrates that moderate taxation can maximize revenue by capturing market share from illicit sources.

New York

New York launched adult-use sales in December 2022 with a complex tax structure: a THC-based excise tax (0.5 cents per milligram for flower, 0.8 cents for concentrates, 3 cents for edibles) plus a 9% retail excise tax and 4% state sales tax. The state projects $1.25 billion in annual revenue once the market matures. New York's rollout has been slow due to licensing delays and illicit market competition, illustrating implementation challenges.

Washington

Washington imposes a 37% excise tax on retail sales, the nation's highest rate. The state collected $559 million in fiscal year 2022-23. Washington eliminated its three-tier tax structure (producer, processor, retailer) in favor of a single retail tax in 2015 to reduce administrative complexity. The high rate has sustained illicit market activity, with an estimated 30% of consumption occurring outside legal channels.

Medical-Only States

States including Mississippi, Missouri (which transitioned to adult-use in 2023), and Utah maintain medical-only programs with lower or zero excise taxes. These states would face significant policy decisions if federal legalization occurs, potentially accelerating adult-use adoption to capture tax revenue.

Market and Business Implications

Federal tax policy will determine whether legal cannabis businesses can achieve profitability, access capital, and compete with illicit markets that generate an estimated $40-60 billion annually. For MSOs, 280E elimination through rescheduling would immediately improve EBITDA margins by 15-25 percentage points. Curaleaf Holdings reported adjusted EBITDA of $362 million on revenue of $1.38 billion in 2023, a 26% margin. With standard deductions, the company estimates margins would reach 40-45%, comparable to alcohol distributors. This would unlock institutional investment, currently limited by federal prohibition and banking restrictions. Capital markets remain constrained. U.S. cannabis companies cannot list on the New York Stock Exchange or NASDAQ due to federal illegality, instead trading on the Canadian Securities Exchange or over-the-counter markets. This limits access to capital and creates higher costs of equity. Rescheduling would not resolve listing barriers, but descheduling would open major exchanges and potentially reduce capital costs by 500-800 basis points. Wholesale pricing has collapsed in mature markets due to oversupply and 280E-driven retail price floors. In Oregon, wholesale flower prices fell from $1,500 per pound in 2016 to under $500 in 2023. Cultivators cannot reduce prices further without operating at a loss due to tax burdens. Federal tax relief could allow price reductions that capture illicit market share, but excessive federal excise taxes could maintain price gaps. The illicit market remains price-competitive in most states. In California, illicit eighth-ounces sell for $20-25 compared to $35-50 in licensed dispensaries. Federal excise taxes above 10-15% would widen this gap, undermining legalization's core goal of eliminating criminal markets. The Congressional Research Service estimated in 2019 that federal excise taxes should not exceed $10 per ounce to maintain price competitiveness. Interstate commerce represents the largest potential market transformation. Currently, each state maintains a closed-loop system requiring in-state cultivation and processing. This creates inefficiencies, with cultivation occurring in high-cost states like Massachusetts (average production cost $1,200 per pound) rather than low-cost regions like California ($400 per pound). Federal legalization with interstate commerce could reduce wholesale prices by 40-60%, but would devastate operators in high-cost states unless transition periods or protections are implemented. Banking access would transform operations. An estimated 70% of cannabis transactions occur in cash due to banking restrictions, creating security risks, tax compliance challenges, and operational inefficiencies. The American Bankers Association estimates that cannabis banking would generate $1.2 billion in annual fee revenue for financial institutions while reducing cash-related crime. However, banking access requires either the SAFE Banking Act or comprehensive legalization; rescheduling alone would not resolve the issue.

What Experts Say

Tax policy experts, industry analysts, and economists have developed consensus around several principles for optimal federal cannabis taxation. The Tax Foundation has recommended a federal excise tax structure based on weight or THC content rather than price, arguing that ad valorem taxes create compliance challenges and distort markets. According to the organization's 2021 analysis, a $50-per-ounce excise tax would generate approximately $7 billion annually while maintaining price competitiveness with illicit markets. The Foundation emphasized that revenue should not be the primary goal; market displacement of illicit sales should take priority. The Congressional Budget Office projected in 2020 that marijuana legalization with a $50-per-ounce excise tax would generate $13.6 billion over ten years, assuming 15% of current illicit users transition to legal markets and consumption increases 10% due to lower prices and easier access. The CBO noted significant uncertainty in these estimates due to unknown federal regulatory structures and state responses. The RAND Corporation published extensive analysis in 2015 warning that high tax rates could sustain illicit markets. According to RAND researchers, optimal tax policy should start with low rates (5-10% excise tax) and increase gradually as legal markets mature and prices decline. The organization recommended against THC-based taxation due to measurement challenges and incentives to manipulate testing. Economists at the University of California, Berkeley estimated in 2023 that federal cannabis taxation could generate $18-25 billion annually if structured as a 10% excise tax combined with normal income taxation after 280E repeal. The researchers emphasized that revenue potential depends critically on state cooperation and avoiding tax rate competition that drives consumers to illicit markets. The National Conference of State Legislatures has advocated for federal-state revenue sharing, arguing that states have borne the costs and risks of legalization and should retain significant tax authority. According to NCSL policy positions, any federal excise tax should be capped at 5-7% with revenue shared back to states based on sales volume. Industry analysts at Cowen & Company estimated that 280E repeal through rescheduling would increase cannabis industry market capitalization by $15-20 billion, or approximately 40-50%, by improving profitability and reducing regulatory risk. The firm projected that major MSOs would achieve investment-grade credit ratings within 2-3 years of 280E elimination, opening access to debt capital markets.

What's Next: Decision Points and Scenarios

Federal cannabis tax policy faces several critical decision points over the next 12-24 months that will shape the industry's trajectory. The DEA's rescheduling decision represents the most immediate catalyst. Administrative law judge hearings on the Schedule III proposal concluded in late 2024, with a final rule expected in 2025 or early 2026. If the DEA finalizes rescheduling, 280E would be eliminated for tax years beginning after the effective date. This would provide immediate relief but would not resolve banking, interstate commerce, or comprehensive legalization questions. Congressional action remains uncertain. The 119th Congress (2025-2026) could consider the SAFE Banking Act as standalone legislation or attached to must-pass bills like the National Defense Authorization Act. Banking reform has bipartisan support but faces opposition from progressive Democrats seeking comprehensive reform and conservative Republicans opposing any cannabis liberalization. Comprehensive legalization through the MORE Act or CAOA appears unlikely in the near term given divided government and competing priorities. However, incremental reforms including 280E repeal, banking access, and modest federal excise taxes could advance through budget reconciliation or bipartisan negotiation. The 2024 presidential election and subsequent administration will significantly influence policy direction. A Democratic administration would likely continue supporting rescheduling and banking reform, while a Republican administration's position would depend on the specific candidate and party platform. Cannabis policy has become less partisan as more states legalize, with recent polling showing 68% public support for legalization across party lines. State-level developments will continue regardless of federal action. Seven states including Florida, North Dakota, and South Dakota have adult-use legalization on the 2024 ballot. If these measures pass, over half of U.S. states would have adult-use programs, increasing pressure on federal reform. International developments may influence U.S. policy. Germany legalized adult-use cannabis in April 2024, joining Canada, Uruguay, and Mexico. The United Nations Commission on Narcotic Drugs reclassified cannabis in 2020, removing it from Schedule IV (most dangerous) of the 1961 Single Convention. Growing international acceptance may reduce U.S. resistance to reform. Three scenarios appear most likely over the next 3-5 years: First, rescheduling to Schedule III without comprehensive legalization. This would eliminate 280E, reduce effective tax rates to 25-35%, and provide significant industry relief. However, banking restrictions, interstate commerce barriers, and federal prohibition would remain. This represents the path of least resistance politically. Second, incremental reform combining rescheduling with SAFE Banking and modest federal excise taxes (5-10%). This would address the most pressing industry concerns while generating federal revenue and maintaining state regulatory authority. This scenario would likely include provisions protecting financial institutions and allowing standard business deductions. Third, comprehensive legalization through descheduling, interstate commerce authorization, and structured federal excise taxes with revenue sharing. This would require significant political will and likely a Democratic trifecta in Congress and the White House. Revenue would fund social equity programs, expungement, and substance abuse treatment. The most likely timeline places rescheduling in 2025-2026, banking reform in 2025-2027, and comprehensive legalization (if it occurs) in 2027-2030. Market participants should prepare for continued uncertainty and state-by-state variation for at least the next 3-5 years.

Further Reading and Primary Sources

• Internal Revenue Code Section 280E (26 U.S.C. § 280E) - https://www.law.cornell.edu/uscode/text/26/280E
• Controlled Substances Act (21 U.S.C. § 801 et seq.) - https://www.deadiversion.usdoj.gov/21cfr/21usc/index.html
• DEA Notice of Proposed Rulemaking on Marijuana Rescheduling (May 2024) - https://www.federalregister.gov/
• HHS Recommendation to Reschedule Marijuana (August 2023) - https://www.hhs.gov/
• Congressional Budget Office, "Budgetary Effects of Legalizing Marijuana" (2020) - https://www.cbo.gov/
• Tax Foundation, "Federal Marijuana Tax Revenue" (2021) - https://taxfoundation.org/
• RAND Corporation, "Considering Marijuana Legalization: Insights for Vermont and Other Jurisdictions" (2015) - https://www.rand.org/
• Californians Helping to Alleviate Medical Problems, Inc. v. Commissioner, 128 T.C. 173 (2007) - https://www.ustaxcourt.gov/
• Olive v. Commissioner, T.C. Memo 2015-149 - https://www.ustaxcourt.gov/
• FinCEN Guidance on Marijuana-Related Businesses (FIN-2014-G001) - https://www.fincen.gov/
• National Conference of State Legislatures, "State Medical Cannabis Laws" - https://www.ncsl.org/
• Marijuana Policy Project, Federal Legislation Tracker - https://www.mpp.org/
• Congressional Research Service, "Marijuana: Medical and Retail—Selected Legal Issues" - https://crsreports.congress.gov/
• U.S. Cannabis Council, Industry Reports and White Papers - https://www.uscannabishouncil.org/
• Cowen Equity Research, Cannabis Industry Analysis (subscription required) - https://www.cowen.com/